Location: Location not imported yet.Title: Foot-and-mouth disease virus SAT1 sequences purified from co-infected Cape buffalo in Kenya
|PALINSKI, RACHELC - Kansas State University|
|SANGULA, ABRAHAM - Kenya Fmd Laboratory- Wrlfmd|
|GAKUYA, FRANCIS - Wildlife Research And Training Institute|
|PAUSZEK, STEVEN - Animal And Plant Health Inspection Service (APHIS)|
|OBANDA, VINCENT - Wildlife Research And Training Institute|
|VANDERWAAL, KIMBERLY - University Of Minnesota|
|OMONDI, GEORGE - University Of Minnesota|
Submitted to: Microbiology Resource Announcements
Publication Type: Other
Publication Acceptance Date: 8/17/2022
Publication Date: 9/12/2022
Citation: Palinski, R., Sangula, A., Gakuya, F., Bertram, M.R., Pauszek, S., Hartwig, E.J., Smoliga, G.R., Obanda, V., Vanderwaal, K., Arzt, J., Omondi, G. 2022. Foot-and-mouth disease virus SAT1 sequences purified from co-infected Cape buffalo in Kenya. Microbiology Resource Announcements. https://doi.org/10.1128/mra.00584-22.
Interpretive Summary: Foot-and-mouth disease virus (FMDV) is an important viral disease affecting animal health and economics through impacts on agriculture and trade. African Cape Buffalo are a reservoir for FMD, and can be infected with multiple serotypes without having clinical signs of disease. This paper reports serotype SAT1 sequences from subclinically infected buffalo in Kenya. Additionally, we report SAT1 sequences acquired through plaque purification of samples from buffalo that were infected with both SAT1 and SAT2. Plaque purification separates the different viruses in a sample, resulting in more accurate sequences than can be obtained by directly sequencing a sample containing multiple viruses.
Technical Abstract: Forty-nine novel foot-and-mouth disease virus SAT1 genomes were acquired from oropharyngeal fluid samples from asymptomatic African Cape buffalo in Kenya in 2016. Sequences were from primary passage or plaque purified SAT1/SAT2 dual infected samples These genomes are important to elucidation of the molecular epidemiology of FMDV persistent and subclinical infections.